Joris Winderickx
Corporate Officer/Principal at reMYND NV
Joris Winderickx active positions
| Companies | Position | Start | End |
|---|---|---|---|
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Corporate Officer/Principal | 2012-05-29 | - |
| Director/Board Member | 2001-12-31 | 2012-05-29 | |
| Founder | 2009-11-08 | - |
Career history of Joris Winderickx
Former positions of Joris Winderickx
| Companies | Position | Start | End |
|---|---|---|---|
| Royal Flemish Chemical Society | Founder | - | - |
ADx NeuroSciences NV
 ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Director/Board Member | - | - |
| Katholieke Universiteit Leuven | Corporate Officer/Principal | - | - |
Training of Joris Winderickx
| Katholieke Universiteit Leuven | Doctorate Degree |
Statistics
International
| Belgium | 5 |
Operational
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Commercial Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
| Royal Flemish Chemical Society | |
ADx NeuroSciences NV
ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Health Technology |
- Stock Market
- Insiders
- Joris Winderickx
- Experience
